類風濕關節炎市場：KOL 洞察

本報告考察了全球類風濕關節炎市場，並提供了市場概述，包括已上市的治療方法、管道趨勢和未來前景。

目錄

執行摘要

治療演算法

研究目標

• 市售治療方法
  • 抗腫瘤壞死因子藥物（Humira、Enbrel、Remicade、Simponi、Cimzia）
  • 白血球介素 6 抑制劑（Actemra/RoActemra、Kevzara）
  • Orencia（Abatacept，Bristol Myers Squibb）
  • Rituxan/Mabthera（Rituximab、Biogen/Roche）
  • Xeljanz（Tofacitinib，Pfizer）
  • Olumiant（Baricitinib、Incyte/Lilly）
  • Rinvoc（upadacitinib，AbbVie）
  • Giseleca（filgotinib，Galapagos）
• 管道療法
  • Dazodarivep（HZN 4920；Amgen）
• 早期進展和其他可能影響 RA 治療的因素
  • 關鍵見解摘要

附錄

While use of anti-TNF therapies remains the first line biologic RA treatment choice, prescribing of IL-6 inhibitors has increased. But do KOLs prefer Roche's Actemra/RoActemra or Sanofi's Kevzara? Experts find Amgen's pipeline anti-CD40 ligand-Tn3 fusion protein dazodalibep to be intriguing, but do they see it finding a place in the crowded RA therapy market? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Companies Listed:

Table of Contents

Executive summary (8)

Treatment algorithm

Research objectives (86)

• Marketed therapies (67)
  • Anti-TNFs (Humira, Enbrel, Remicade, Simponi, Cimzia) (8)
  • Interleukin-6 inhibitors (Actemra/RoActemra, Kevzara) (10)
  • Orencia (abatacept; Bristol Myers Squibb) (10)
  • Rituxan/MabThera (rituximab; Biogen/Roche) (8)
  • Xeljanz (tofacitinib; Pfizer) (10)
  • Olumiant (baricitinib; Incyte/Lilly) (7)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Jyseleca (filgotinib; Galapagos) (6)
• Pipeline therapies (5)
  • dazodalibep (HZN 4920; Amgen) (5)
• Earlier-stage developments and other factors that may impact RA treatment (12)
  • Key insights summary (12)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)